Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIONS: Acthar Gel in RRMS Relapse
NCT03126760Phase 4Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Acthar Gel with Placebo (2 arms). Primary endpoint: Expanded Disability Status Scale at Day 42. Started May 2017; status: terminated.
02
Drugs
repository corticotropin injection
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03126760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126760.